- Home
- SGN vs ENSC Comparison
SGN vs ENSC Comparison
Compare SGN & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- ENSC
- Stock Information
- Founded
- SGN 2019
- ENSC 2003
- Country
- SGN United States
- ENSC United States
- Employees
- SGN N/A
- ENSC N/A
- Industry
- SGN
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- SGN
- ENSC Health Care
- Exchange
- SGN Nasdaq
- ENSC Nasdaq
- Market Cap
- SGN 7.8M
- ENSC 6.4M
- IPO Year
- SGN 2023
- ENSC N/A
- Fundamental
- Price
- SGN $1.19
- ENSC $1.68
- Analyst Decision
- SGN
- ENSC
- Analyst Count
- SGN 0
- ENSC 0
- Target Price
- SGN N/A
- ENSC N/A
- AVG Volume (30 Days)
- SGN 89.7K
- ENSC 79.2K
- Earning Date
- SGN 11-12-2025
- ENSC 11-14-2025
- Dividend Yield
- SGN N/A
- ENSC N/A
- EPS Growth
- SGN N/A
- ENSC N/A
- EPS
- SGN N/A
- ENSC N/A
- Revenue
- SGN $366,344.00
- ENSC $4,487,973.00
- Revenue This Year
- SGN N/A
- ENSC N/A
- Revenue Next Year
- SGN N/A
- ENSC N/A
- P/E Ratio
- SGN N/A
- ENSC N/A
- Revenue Growth
- SGN N/A
- ENSC 1.51
- 52 Week Low
- SGN $0.44
- ENSC $1.53
- 52 Week High
- SGN $8.60
- ENSC $10.96
- Technical
- Relative Strength Index (RSI)
- SGN 35.75
- ENSC 30.16
- Support Level
- SGN $1.15
- ENSC $1.53
- Resistance Level
- SGN $1.61
- ENSC $2.17
- Average True Range (ATR)
- SGN 0.11
- ENSC 0.14
- MACD
- SGN -0.01
- ENSC -0.04
- Stochastic Oscillator
- SGN 9.64
- ENSC 24.81
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.